Your browser doesn't support javascript.
loading
Effect of Extended 30 µg Ethinyl Estradiol with Continuous Low-Dose Ethinyl Estradiol and Cyclic 20 µg Ethinyl Estradiol Oral Contraception on Adolescent Bone Density: A Randomized Trial.
Gersten, Janet; Hsieh, Jennifer; Weiss, Herman; Ricciotti, Nancy A.
Afiliación
  • Gersten J; New Age Medical Research Corporation, Miami, Florida. Electronic address: jkgersten@gmail.com.
  • Hsieh J; Teva Branded Pharmaceutical Products R&D, Inc, West Chester, Pennsylvania.
  • Weiss H; Teva Global Medical Affairs, Petach Tikva, Israel.
  • Ricciotti NA; Teva Branded Pharmaceutical Products R&D, Inc, Frazer, Pennsylvania.
J Pediatr Adolesc Gynecol ; 29(6): 635-642, 2016 Dec.
Article en En | MEDLINE | ID: mdl-27287084
STUDY OBJECTIVE: To compare changes in lumbar spine bone mineral density after 12 months of a 91-day extended regimen or 28-day combined oral contraceptive with those in a healthy reference group not using hormonal contraceptives. DESIGN: Phase 2, multicenter, open-label, randomized, controlled study. SETTING: Forty-five academic centers, clinical research centers, and community practices in the United States. PARTICIPANTS: Eight hundred twenty-nine postmenarcheal adolescent girls aged 12-18 years. INTERVENTIONS: Adolescents were randomly assigned to 91-day levonorgestrel (LNG)/ethinyl estradiol (EE) extended regimen (84 days of LNG 150 µg/EE 30 µg with 7 days of EE 10 µg [LNG/EE extended regimen]) or 28 days of LNG/EE (21 days of LNG 100 µg/EE 20 µg with 7 days of placebo [LNG/EE 21/7]) for 12 months. A reference group not seeking hormonal contraception was also evaluated. MAIN OUTCOME MEASURES: The primary end point was mean percent change in lumbar spine bone mineral density measured using dual-energy x-ray absorptiometry. RESULTS: Of 1361 adolescents randomized/enrolled, 829 were included in the primary analysis. Mean changes in lumbar spine bone mineral density were +2.26% with LNG/EE extended regimen, +1.45% with LNG/EE 21/7, and +2.50% in the reference group. Noninferiority of the LNG/EE extended regimen compared with the reference group was shown. A statistically significant treatment difference was found between LNG/EE 21/7 and the reference group (1.05%; 95% confidence interval, 0.61%-1.49%) but not between LNG/EE extended regimen and the reference group (0.23%; 95% confidence interval, -0.20% to 0.67%). No new safety signals were noted. CONCLUSION: Compared with the reference group, bone accrual was statistically significantly lower among LNG/EE 21/7 users but not among LNG/EE 30-µg extended regimen users. Additional research is needed to clarify the clinical relevance of these findings.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Densidad Ósea / Levonorgestrel / Anticonceptivos Orales Combinados / Etinilestradiol Tipo de estudio: Clinical_trials Límite: Adolescent / Child / Female / Humans Idioma: En Revista: J Pediatr Adolesc Gynecol Asunto de la revista: GINECOLOGIA / PEDIATRIA Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Densidad Ósea / Levonorgestrel / Anticonceptivos Orales Combinados / Etinilestradiol Tipo de estudio: Clinical_trials Límite: Adolescent / Child / Female / Humans Idioma: En Revista: J Pediatr Adolesc Gynecol Asunto de la revista: GINECOLOGIA / PEDIATRIA Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos